Full-Time

Sr. Director/Executive Director

Head of Translational Research

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Senior, Expert

Somerset County, NJ, USA

Part of the Research & Development team based in Somerset, NJ.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD or MD in biology, immunology, biochemistry or related field
  • At least 15 years of relevant work experience, including a minimum of 10 years of experience in pharmaceutical or biotech industry. Experience in cell therapy clinical development is preferred. Knowledge and experience in CDx development are plus
  • In depth Knowledge of immunology and tumor biology
  • Strong background in clinical biomarker analysis, research tools, technology and assay platforms
  • Excellent communication and writing skills
  • Ability to work effectively and collaboratively in cross functional teams
  • Language: English
Responsibilities
  • Lead translational team, and provide preclinical and clinical translational support for Legend pipeline development
  • Coach and lead translational representatives in cross functional development teams; Collaborate with discovery, preclinical development, CMC and clinical teams to accelerate the product pipeline
  • Establish translational biomarker strategy in alignment with clinical development objectives; Lead translational safety investigation, develop MOA hypothesis and identify key characteristics relevant to efficacy and treatment failure
  • Work closely with clinical and regulatory teams in investigator brochures, IND applications, clinical protocols, and other clinical and regulatory documents when appropriate
  • Accountable for patient selection strategies, CDx development, approval and implementation
  • Provide oversight and management to CROs and academic collaborations

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates within the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Unlike many competitors, Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for hard-to-treat diseases through innovative cell therapy solutions.

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

20%

1 year growth

47%

2 year growth

106%
Simplify Jobs

Simplify's Take

What believers are saying

  • Legend Biotech's recent European Commission approval for CARVYKTI® positions it as a leader in the multiple myeloma treatment market.
  • Strategic partnerships, such as the one with MaxCyte, enhance Legend Biotech's capabilities in cell engineering and expand its technological reach.
  • The company's commitment to transparency and investor relations, demonstrated through regular financial updates, fosters investor confidence and long-term stability.

What critics are saying

  • The competitive landscape in cell therapy and personalized medicine is intense, requiring continuous innovation to maintain market position.
  • Regulatory hurdles and the need for extensive clinical trials can delay the commercialization of new therapies, impacting revenue streams.

What makes Legend Biotech unique

  • Legend Biotech's technology-agnostic approach allows it to explore multiple innovative therapies, unlike competitors who may focus on a single technology.
  • The company's comprehensive business model, from discovery to commercialization, ensures control over the entire treatment lifecycle, providing a competitive edge.
  • Legend Biotech's strong focus on CAR-T therapies, particularly for hematological malignancies and solid tumors, sets it apart in the personalized medicine sector.

Help us improve and share your feedback! Did you find this helpful?